Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded a license agreement for exclusive rights to develop, manufacture and commercialize SMP-986 in Japan, a new investigational compound for overactive bladder created by Dainippon.
Completing Phase II studies in Japan, Europe and the USA, Dainippon says it was searching for a partner with a strong presence in urology. As a result, it chose Nippon Shinyaku as its best partner for the Japanese market.
Undisclosed upfront and milestone payments to be made
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze